Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition

Yu Toyoda¹ *, Tappei Takada¹, Hiroshi Miyata¹, Toshihisa Ishikawa²*, Hiroshi Suzuki¹

¹ Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, ² RIKEN Center for Life Science Technology, Yokohama, Japan

* Current address: NGO Personalized Medicine & Healthcare, Yokohama, Japan
* ytoyoda-ky@umin.ac.jp

Abstract

ATP-binding cassette C11 (ABCC11) is a plasma membrane protein involved in the transport of a variety of lipophilic anions. ABCC11 wild-type is responsible for the high-secretion phenotypes in human apocrine glands, such as that of wet-type ear wax, and the risk of axillary osmidrosis. We have previously reported that mature ABCC11 is a glycoprotein containing two N-linked glycans at Asn838 and Asn844. However, little is known about the role of N-linked glycosylation in the regulation of ABCC11 protein. In the current study, we investigated the effects of N-linked glycosylation on the protein level and localization of ABCC11 using polarized Madin-Darby canine kidney II cells. When the N-linked glycosylation in ABCC11-expressing cells was chemically inhibited by tunicamycin treatment, the maturation of ABCC11 was suppressed and its protein level was significantly decreased. Immunoblotting analyses demonstrated that the protein level of the N-linked glycosylation-deficient mutant (N838Q and N844Q: Q838/844) was about half of the ABCC11 wild-type level. Further biochemical studies with the Q838/844 mutant showed that this glycosylation-deficient ABCC11 was degraded faster than wild-type probably due to the enhancement of the MG132-sensitive protein degradation pathway. Moreover, the incubation of ABCC11 wild-type-expressing cells in a low-glucose condition decreased mature, glycosylated ABCC11, compared with the high-glucose condition. On the other hand, the protein level of the Q838/844 mutant was not affected by glucose condition. These results suggest that N-linked glycosylation is important for the protein stability of ABCC11, and physiological alteration in glucose may affect the ABCC11 protein level and ABCC11-related phenotypes in humans, such as axillary osmidrosis.
Introduction

Accumulating evidence suggests that ATP-binding cassette (ABC) transporter proteins play a pivotal role in the maintenance of human health [1–5]. Thereby, many studies in recent years have focused on not only the molecular function of each ABC protein but also the regulatory mechanisms responsible for their protein levels and localization in cells. Human ABCC11 (multidrug resistance-associated protein 8, MRP8) is a member of the ABC protein family [6–9]. Its gene encodes a 1382-amino acid transporter protein that contains two ATP-binding casquettes and twelve transmembrane helices. Based on the predicted topology, both the N-terminus and the C-terminus of the ABCC11 protein are thought to be located on the cytoplasmic side of the membrane [7]. Like other ABC transporter proteins [4], ABCC11 is able to transport a variety of compounds across membranes at the cost of ATP hydrolysis. The substrates of ABCC11 include endogenous substances, such as cyclic nucleotides and several sulfated conjugates, as well as drugs such as 5-fluorouracil (5-FU) and methotrexate [9–13]. Transcript analyses revealed that ABCC11 mRNA is ubiquitously expressed in human tissues [14, 15]. Moreover, some immunohistochemical studies demonstrated that the ABCC11 protein is localized on the apical membrane of polarized cells in human apocrine glands in vivo [16] and in a cultured cell line expressing recombinant human ABCC11 in vitro [17].

Previously, we and collaborators reported that a single nucleotide polymorphism (SNP) in ABCC11, 538G>A (rs17822931: Gly180Arg), is the determinant of human earwax [18], a well-known Mendelian trait and one of the apocrine gland-related phenotypes. The 538GG (wild type; WT homozygote) and GA (heterozygote) genotype give a wet phenotype, whereas the 538AA (SNP-type homozygote) gives a dry (secretion-deficient) phenotype. The fact that the 538A allele gives a recessive phenotype is strongly supported by our previous study demonstrating that this SNP variant is recognized as an endoplasmic-reticulum-associated protein degradation (ERAD) substrate and therefore loses its protein function [16]. Furthermore, ABCC11 538G>A is reportedly associated with other apocrine gland-related phenotypes, such as apocrine colostrum secretion from mammary glands [19] and axillary osmidrosis [16, 20–22]. In many cases, the 538G allele corresponds to high-secretory phenotypes and the 538A allele corresponds to low-secretory phenotypes, suggesting the involvement of ABCC11 in the physiological regulation of human apocrine glands [8, 16]. Axillary osmidrosis is a distressing condition characterized by strong body odor and profuse sweating from armpits resulting from excessive apocrine secretion. Thus, the inhibition of ABCC11 is considered to be an effective way to prevent and/or treat axillary osmidrosis. However, to date little is known about the regulatory mechanisms of the ABCC11 protein in apocrine glands, although they should include potential targets for ABCC11 inhibition. Accordingly, the investigation of the molecular basis related to the regulation of ABCC11 would be an important issue.

We have previously revealed that ABCC11 is glycosylated at both Asn838 and Asn844, found in the extracellular loop of the ABCC11 protein [16]. Asparagine (N)-linked glycosylation is one of the most important post-translational modifications and participates in many cellular mechanisms that contribute to health and disease of humans, such as protein folding, stability, and intracellular trafficking [23, 24]. In fact, being implemented in one of the protein quality control systems, N-glycosylation affects the protein level and/or localization of physiologically important transporters [25–29]. At present, however, the role of N-linked glycosylation in the regulation of ABCC11 is not well understood, although the glycosylation is a known post-translational modification of ABCC11. Regarding this unsolved issue, our previous study was restricted in the determination of N-linked glycosylation sites in ABCC11 expressed only in non-polarized Flp-In-293 cells [16]. Considering that the physiological expression of ABCC11 protein has been confirmed only in polarized cells in human body, we should
investigate the effect of N-linked glycan on the protein expression, stability, and localization of ABCC11 using polarized cells.

In the present study, we expressed ABCC11 WT and N-linked glycosylation-deficient N838Q and/or N844Q mutant(s) in Madin-Darby canine kidney II (MDCKII) cells, and then compared the protein levels and localization of each ABCC11 mutant. The disruption of N-linked glycosylation resulted in the decrease of the ABCC11 protein level and enhanced protein degradation, whereas exclusion of N-linked glycan did not affect the localization of ABCC11. These findings suggest the role of N-linked glycan in increasing the protein stability of ABCC11 in polarized cells, a cell type that the physiological expression of ABCC11 protein has been confirmed.

Materials and Methods

Materials

The following compounds were purchased from commercial sources that are indicated in parentheses: tunicamycin and bafilomycin A₁ (Wako Pure Chemical Industries Ltd., Tokyo, Japan); 5-fluorouracil (5-FU) and cycloheximide (Nacalai Tesque, Inc., Kyoto, Japan); Peptide N-glycosidase F (PNGase F) (New England Biolabs, Inc., Ipswich, MA, USA); MG132 (Calbiochem, Darmstadt, Germany). All other chemicals used were commercially available and of analytical grade.

Construction of ABCC11-containing expression vectors

The full-length ABCC11 WT (NCBI accession; NM_033151) open reading frame (ORF) in pcDNA3.1/hygro(-) plasmid, constructed in our previous study [16], was amplified with the SalI site attached at the 5'-end and with the BamHI site at the 3'-end by PCR, and then inserted into the pEGFP-C1 vector plasmid (Clontech Laboratories, Inc., Palo Alto, CA, USA) for CMV-driven expression of EGFP-ABCC11 in mammalian cells. In a similar manner, ABCC11 ORF without the termination codon was inserted into the SalI and the BamHI sites of the pEGFP-N1 vector (Clontech Laboratories, Inc.) for the expression of ABC-C11-EGFP. As a negative or positive control protein for localizing on the apical membrane of MDCKII cells, we chose a glucose transporter type 9 isoform a (long form variant) and b (short form variant) (GLUT-9a and b, also known as solute carrier family 2 member 9; SLC2A9a and b, NCBI accession; NM_020041.2 and NM_001001290, respectively) [30] and constructed the expression vector for GLUT-9a-EGFP and GLUT-9b-EGFP with a similar strategy, respectively. As another positive control gene in ABC transporter family, we used ABCG2 (NCBI accession; NM_004827) ORF in pEGFP-C1 vector (Clontech Laboratories, Inc.) for the expression of EGFP-ABCG2 [31]. Using a site-directed mutagenesis technique, several mutants of ABCC11 lacking the N-linked glycosylation site(s) (N838Q, N844Q, N838/844Q) were constructed with a pEGFP-N1 vector according to our previous study [16]. The construct of N-linked glycosylation-deficient ABCG2 mutant (N596Q) was constructed with a similar strategy. Introduction of mutations was confirmed by full sequencing using BigDye® Terminator v3.1 (Applied Biosystems Inc., Foster City, CA, USA) with Applied Biosystems® 3130 Genetic Analyzer (Applied Biosystems Inc.) according to the manufacturer’s protocol.

Cell culture and transfection

MDCKII cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, 4.5 g/L glucose with L-Gln and sodium pyruvate) (Nacalai Tesque) supplemented with 10% fetal bovine
serum (FBS) (Biowest, Nuaille, France), and 1% penicillin-streptomycin (Nacalai Tesque) at 37°C in a humidified atmosphere of 5% (v/v) CO₂ in air as described previously [32]. Each vector plasmid for ABCC11 WT or its mutants was transfected into MDCKII cells by using polyethyleneimine MAX (PEI-MAX) (Polysciences Inc., Warrington, PA, USA) as described previously [33] with some modification. The amount of plasmid DNA used for transfection was adjusted to be the same for ABCC11 WT and its mutants. In brief, each plasmid was mixed with PEI-MAX (1 μg of plasmid/5 μL of PEI-MAX for 5 × 10⁵ cells of MDCKII) in Opti-MEM™ (Invitrogen, Carlsbad, CA, USA) and incubated for 20 min at room temperature. MDCKII cells were collected after the treatment with a 2.5 g/L-Trypsin and 1 mmol/L-EDTA solution (Nacalai Tesque), followed by centrifugation at 1,000 × g for 5 min. The cell pellet was re-suspended in fresh DMEM, and the resulting suspension was mixed with plasmid/PEI-MAX mixture (50:50, v/v). Then, the MDCKII cells were re-seeded onto cell culture plates at a concentration of 1.4 × 10⁵ cells/cm². The medium was replaced with fresh medium after the first 8 h of incubation. For the selection and maintenance of stable transfectants (MDCKII/ABCC11 WT-EGFP), transfected cells were cultured in the presence of 2.5 mg/mL G418 sulfate (Nacalai Tesque). To examine the effect of glucose level in culture medium on the ABCC11, DMEM with glucose (1.0 g/L (low) and 4.5 g/L (high)) with L-Gln and sodium pyruvate, (Nacalai Tesque) supplemented with 10% FBS and 1% penicillin-streptomycin was used in the experiments.

Human embryonic kidney 293 (HEK293) cells (Life technologies, Tokyo, Japan) and 293A cells (Invitrogen) were maintained in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, 2 mM L-Glutamine (Nacalai Tesque), and 1 × Non-Essential Amino Acid (Life Technologies) in a similar manner as described above. Before transfection, HEK293 cells were seeded onto cell culture plates at a concentration of 1.4 × 10⁵ cells/cm². Twenty-four hours after the seeding, each plasmid vector was transiently transfected to the cells using PEI-MAX (1 μg of plasmid/5 μL of PEI-MAX in Opti-MEM™). The medium was replaced with fresh medium after the first 8 h of incubation.

**Construction and infection of recombinant adenovirus**

Recombinant adenovirus for the expression of human ABCC11 WT was constructed using a ViraPower™ Adenovial Gateway™ Expression Kit (Invitrogen) according to the manufacturer’s protocol. In brief, the full-length ABCC11 WT ORF was inserted into pAd/CMV/V5-DEST™ Gateway Vector plasmid. After the digestion of the plasmid with Pac I (New England Biolabs) treatment for two hours at 37°C, the linearized construct containing the plasmid region for the proper packaging and production of adenovirus and the expression of non-tagged ABCC11 was purified, and then used to transfect into 293A adenovirus producer cells. Several days after the transfection, a crude viral lysate was prepared from the harvest cells and used for the infection of newly seeded 293A cells to amplify the adenovirus. After the amplification, the adenovirus was purified using an Adenovirus (Ad5) Purification and Concentration Kit (AdenoPACK 20; Sartorius, Goettingen, Germany) according to the manufacturer’s instruction, and stored at -80°C until use. Then, the resulting adenovirus titer was determined using an Adeno-X™ Rapid Titer Kit (Clontech). As a control adenovirus, EGFP-expressing adenovirus was constructed with a similar strategy.

MDCKII cells were plated onto cell culture plates at a density of 1.4 × 10⁵ cells/cm². After 12 h, cells were infected with recombinant adenoviruses harboring non-tagged human ABCC11 WT or EGFP at indicated multiplicity of infections (MOIs) as described previously [34]. At 48 h after the infection, the culture medium was replaced with fresh medium with or without tunicamycin, and the cells were cultured for further 24 h.
Preparation of whole cell lysate

At indicated times after the plasmid transfection, MDCKII cells or HEK293 cells were washed by ice-cold phosphate-buffered saline without potassium; PBS (-) twice, and were harvested using a cell scraper. After centrifugation at 800 × g for 5 min, cells were treated with cell lysis buffer A containing 50 mM Tris/HCl (pH 7.4), 1 mM dithiothreitol, 1% (v/v) Triton X-100, and a protease inhibitor cocktail for general use (Nacalai Tesque). The cell suspension samples were homogenized by passage through a 27-gauge needle equipped with 1 mL disposable plastic syringe (Terumo Corp., Tokyo, Japan) 10 times. The homogenate was centrifuged at 3,000 × g at 4°C for 10 min and the resulting supernatant (whole cell lysate) was collected in a new tube. Protein concentration of whole cell lysate was quantified using BCA Protein Assay Kit (Pierce, Rockford, IL, USA) with BSA as a standard according to the manufacturer’s protocol.

Glycosidase treatment

For glycosidase treatment, the whole cell lysate samples were incubated with PNGase F (1.25 U/μg of protein) at 37°C for 10 min as described previously [16], and then subjected to immunoblotting analysis. In the current study, the levels of total ABCC11 protein (glycosylated and non-glycosylated) in cells were determined using PNGase F-treated samples. The PNGase F-treated sample was used also as a control indicating the band position for non-glycosylated ABCC11 in immunoblotting analyses.

Immunoblotting analysis

EGFP-fused ABCC11 WT and its mutants expressed in MDCKII cells were detected by immunoblotting with a rabbit anti-EGFP polyclonal antibody (A11122; Life technologies). Non-tagged ABCC11 expressed in HEK293 cells and ABCC11-expressing adenovirus-infected MDCKII cells was detected with a rat anti-ABCC11 monoclonal antibody (M8I-74; Abcam Inc., Cambridge, MA, USA). In brief, at first, whole cell lysate samples with or without PNGase F treatment were mixed with SDS-PAGE sample buffer solution containing 10% (v/v) 2-mercaptoethanol. Thereafter, samples were electrophoretically separated on 7.5% (v/v) poly-acrylamide gels, and then transferred to Hybond™ nitrocellulose membrane (GE Healthcare UK Ltd., Buckinghamshire, UK) by electroblotting at 15 V for 70 min. For blocking, the membrane was incubated with Tris-buffered saline containing 0.05% (v/v) Tween 20 (TTBS) and 5% (w/v) skim milk, at 4°C overnight.

Immunoblotting was performed by using the anti-GFP antibody diluted 1,000-fold in TTBS containing 5% skim milk as the first antibody and a donkey anti-rabbit IgG-horseradish peroxidase (HRP)-conjugate (NA934V; GE Healthcare UK Ltd.) diluted 3,000-fold as the second antibody. To detect α-tubulin protein as an internal loading control, we used a rabbit anti-α-tubulin antibody (ab15246; Abcam Inc.) diluted 1,000-fold as the first antibody and the donkey anti-rabbit IgG-HRP-conjugate diluted 3,000-fold as the second antibody. To detect non-tagged ABCC11 protein, we used the anti-ABCC11 antibody diluted 100-fold as the first antibody and a goat anti-rat IgG-HRP-conjugated (NA935V; GE Healthcare UK Ltd.) diluted 2,000-fold as the second antibody. For the detection of 135-kD glycoprotein (gp135) expressed in MDCKII cells, we used a mouse anti-gp135 monoclonal antibody [35] (3F2/D8; the Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA, USA) diluted 100-fold as the first antibody and a sheep anti-mouse IgG-HP-conjugated (NA931V; GE Healthcare UK Ltd.) diluted 3,000-fold as the second antibody. The 3F2/D8 was deposited to the DSHB by Ojakian, G.K. (DSHB Hybridoma Product 3F2/D8). HRP-dependent luminescence was developed with ECL™ Prime Western Blotting Detection Reagent (GE Healthcare UK Ltd.) and detected using a multi-imaging Analyzer Fusion Solo 4™ system (Vilber Lourmat, Eberhardzell,
Germany). The band density was quantified with Fusion software (Vilber Lourmat) to assess the protein expression levels of ABCC11 WT and its mutants.

**Cell staining and confocal laser scanning microscopic observation**

For confocal laser scanning microscopic observation, MDCKII cells transiently transfected with various ABCC11-containing vectors or control vector were plated onto a collagen-coated glass bottom dish (cover size 22 × 22 mm and 0.16–0.19 mm thick; Matsunami Glass Inc., Tokyo, Japan), 72 h prior to the experiments. After fixation with ice-cold methanol for 10 min, and washed three times with PBS (-). For the staining of endogenous gp135 protein in MDCKII cells as an apical membrane marker [36], fixed-MDCKII cells were incubated with the mouse anti-gp135 monoclonal antibody diluted 100-fold in PBS (-) containing 1% BSA (BSA-PBS) as the first antibody for one hour at room temperature, then washed three times with BSA-PBS. Subsequently, cells were further incubated with a goat anti-mouse IgG-Alexa Fluor® 546-conjugate (A11003; Invitrogen) as the second antibody for one hour at room temperature in the dark. After the washing by BSA-PBS three times, cells were incubated with TO-PRO®-3 Iodide (Molecular Probes, Eugene, OR, USA) diluted 250-fold in PBS (-) for 10 min at room temperature to visualize the nuclei of cells. Then, the cells were mounted in VECTASHIELD® Mounting Medium (Vector Laboratories, Burlingame, CA, USA). To analyze the localization of EGFP-fused ABCC11 protein, fluorescence was detected using FluoView™ FV1000 confocal laser scanning microscope (Olympus, Tokyo, Japan).

**WST-8 assay**

To evaluate cellular resistance to 5-FU, the viability of MDCKII cells stably expressing ABC-C11-EGFP or EGFP (mock) were detected using a Cell Count Reagent SF (Nacalai Tesque) according to a manufacturer’s protocol with some modifications as described previously [37]. In brief, cells were seeded at 1 × 10⁴ cells per well into 96-well cell culture plates and pre-cultured for 24 h. After 84 h of incubation with 5-FU at various concentrations, the culture medium was replaced with 100 μL of fresh medium containing 10% (v/v) of the reagent for WST-8 assay. After 2 h of further incubation, the absorbance at 450 nm derived from WST-8-formazan in culture medium was measured using a Varioskan™ Flash Multimode Reader (Thermo Fisher Scientific K.K., Yokohama, Japan).

**Quantification of mRNA expression by real-time PCR**

Total RNA was extracted using RNA isoPlus® Reagent (Takara, Shiga, Japan) from MDCKII cells, according to the manufacturer’s protocol. First-strand cDNA was prepared from the extracted total RNA in a reverse transcriptase reaction with ReverTra Ace® qPCR RT Kit (TOYOBO, Osaka, Japan), and was used as a template for the following quantitative RT-PCR (qRT-PCR). To examine the mRNA levels of ABCC11 and β-actin, the cDNA was amplified by qRT-PCR with SYBR® GreenER™ qPCR SuperMix Universal (Life Technologies) in an Eco Real-Time PCR System (Illumina, San Diego, CA, USA) using the following specific primer sets: human ABCC11 (5'-GACAGAGATTGGAGAGCGGG-3'; 5'-CTGACCGGTCGGAATA GACGG-3'); β-actin (5'-CCCGGAAGGAAACTGACAGC-3'; 5'-GTGCGTGGAAGACGCC TGC-3'). The qRT-PCR reaction was initiated with incubation at 50°C for 2 min, followed by 95°C for 10 min. The cycling protocol consisted of 2 steps: at 95°C for 15 sec and 60°C for 1 min, for 40 cycles. Finally, an additional incubation was performed for the construction of a dissociation curve. Acquisition of qRT-PCR data and subsequent analyses were carried out using Eco software ver 3.0 (Illumina). The expression levels of each gene were calculated using
a standard curve prepared by serial dilution of the reference sample. The expression levels of ABCC11 were normalized by those of β-actin.

**ABCC11 protein stability**

Cycloheximide, an inhibitor of protein translation, was added at 72 h after plasmid transfection to MDCKII cells, and then the cells were collected at 0, 3, 6, and 12 h. MG132, an inhibitor of proteasomal protein degradation, or bafilomycin A1, an inhibitor of lysosomal protein degradation, was added at 48 h after the transfection, and the cells were cultured for further 24 h. The protein levels of ABCC11 in each sample were examined by immunoblotting analysis as described above.

**Multiple sequence alignment**

Amino acid sequences of ABCC11 in several species were obtained from NCBI Entrez database. Multiple sequence alignment and homology calculation were carried out using the GENETYX ver.9 software (GENETYX Co., Tokyo, Japan) with the ClustalW 2.1 Windows program according to the manufacturer’s instruction.

**Statistical analysis**

All statistical analyses were performed by using EXCEL 2013 (Microsoft Corp., Redmond, WA, USA) with Statcel3 add-in software (OMS publishing Inc., Saitama, Japan). Different statistical tests were used for different experiments as described in figure legends. The significance of each value was determined when the P value was less than 0.05 and 0.01.

**Results**

**Expression of EGFP-fused ABCC11 in MDCKII cells**

In order to visualize human ABCC11 protein in MDCKII cells, we constructed two types of expression vectors for ABCC11 fused with EGFP at the C-terminal (ABCC11-EGFP) or N-terminal (EGFP-ABCC11) in the cytosolic domain of ABCC11 (Fig 1A). We first characterized each EGFP-fused ABCC11 protein expressed in MDCKII cells. Expression of human ABCC11 WT fused with EGFP was examined by immunoblotting analysis (Fig 1B) 72 h after the transfection. As shown in Fig 1B, both ABCC11-EGFP and EGFP-ABCC11 were detected as two bands, and PNGase F treatment shifted these immunoreactive bands to another, lower band with a molecular weight of about 180,000. This molecular weight is consistent with that estimated from each cDNA of ABCC11 fused with EGFP, suggesting that the position of the EGFP-tag did not affect the pattern of ABCC11 glycosylation in MDCKII cells. Unfortunately, non-tagged ABCC11 induced by plasmid transfection into MDCKII cells was undetectable with immunoblotting using the anti-ABCC11 antibody (S1 Fig). This result was probably due to the lower sensitivity of the anti-ABCC11 antibody as compared with the anti-EGFP antibody and the low efficiency of plasmid transfection in MDCKII cells. However, both non-tagged ABCC11 protein and ABCC11-EGFP protein transiently expressed in HEK293 cells were detected by immunoblotting using the anti-ABCC11 antibody (Fig 1C) as similar intensity and band pattern except for the different estimated molecular weight, suggesting that the presence of EGFP-tag did not affect the glycosylation pattern and protein level of glycosylated-ABCC11 protein. In order to examine the localization of ABCC11 in MDCKII cells, we performed confocal microscopic observation of MDCKII cells 72 h after the transfection (Fig 1D). At that time, EGFP-tagged GLUT-9b, an apical membrane protein in kidney cells [30], was co-localized with endogenous gp135 protein, an apical membrane marker in MDCKII cells, whereas
EGFP-tagged GLUT-9a, a basal membrane protein in kidney cells [30], was not co-localized with gp135. These results demonstrate the successful construction of polarization and the presence of apical sorting system in MDCKII cells used in the present study. Furthermore, both ABCC11-EGFP and EGFP-ABCC11 showed an apical localization in MDCKII cells (Fig 1D), as did GLUT-9b-EGFP. This result reflects the physiological localization of ABCC11 in polarized cells in apocrine glands [16] and is consistent with the previous report [17]. In addition,

![Diagrams](image-url)

**Fig 1.** Characterization of ABCC11 fused with EGFP, expressed in MDCKII cells. (A) Schematic illustration of ABCC11 protein. ABCC11 has two N-linked glycosylation sites, N838 and N844, in an extracellular loop between transmembrane helices 7 and 8. (B) Glycosylation status and expression of ABCC11-EGFP and EGFP-ABCC11 in MDCKII cells. Cell lysates were prepared 72 hours after the transfection, and subsequently subjected to immunoblotting after treatment with or without PNGase F. The immunoreactive bands, corresponding to the glycosylated forms (Gs) of EGFP-fused ABCC11 protein, were disappeared after PNGase F treatment. The apparent molecular weight value of the non-glycosylated form (Non-G) of EGFP-fused ABCC11 protein was about 180,000. α-Tubulin: a loading control. (C) Glycosylation status and expression of non-tagged ABCC11 and ABCC11-EGFP in HEK293 cells. Cell lysates were prepared 72 hours after the transfection and treated with or without PNGase F, and subsequently subjected to immunoblotting using the anti-ABCC11 antibody. α-Tubulin: a loading control. (D) Apical localization of ABCC11-EGFP and EGFP-ABCC11 in MDCKII cells 72 hours after the transfection. An endogenous apical membrane marker gp135 was immunostained using anti-gp135 antibody (red). Nuclei were stained with TO-PRO-3 iodide (gray). All panels show the Z-sectioning images. Mock (EGFP): a control vector; GLUT-9b-EGFP: a positive control for apical localization; GLUT-9a-EGFP: a negative control for apical localization. (E) 5-fluorouracil (5-FU) resistance activity of MDCKII/mock cells and MDCKII/ABCC11 WT-EGFP cells. Data are expressed as mean ± S.E.M. n = 8. Where vertical bars are not shown, the S.E.M. was contained within the limits of the symbol. Statistical analyses for significant differences were performed according to Student’s t test (*, P < 0.01 compared with mock).

doi:10.1371/journal.pone.0157172.g001
MDCKII cells stably expressing ABCC11-EGFP were more resistant to 5-FU, an anti-cancer drug, than mock MDCKII cells which were constructed with a pEGFP-N1 vector (Fig 1E). Considering the ability of ABCC11 to efflux 5-FU and its active metabolite 5-fluoro-2’-deoxy-yuridine 5’-monophosphate [10], this drug resistance suggests that ABCC11-EGFP is expressed in MDCKII cells in its functional form. Therefore, we used the construct of ABC-C11-EGFP in the following studies.

Complete absence of N-linked glycosylation decreases ABCC11 protein levels

In order to investigate the significance of N-linked glycosylation in the regulation of ABCC11 protein, we conducted biochemical evaluations. At first, we examined the effect of tunicamycin, an N-linked glycosylation inhibitor, on the protein levels of ABCC11. The tunicamycin-treatment of MDCKII cells transiently expressing ABCC11-EGFP blocked ABCC11 glycosylation, and shifted the higher molecular weight bands (glycosylated forms) to a lower band with a molecular weight of about 180,000 (non-glycosylated form) (Fig 2A). To analyze the effect of tunicamycin on the protein levels of ABCC11, we treated all samples with PNGase F to remove N-linked glycan, resulting in the detection of a single band in immunoblotting (Fig 2B). Quantitative evaluation of the single bands revealed that the protein levels of ABCC11 in the tunicamycin-treated cells were lower than those in non-treated cells (Fig 2B). Furthermore, we examined the effect of tunicamycin treatment on the protein levels of non-tagged ABCC11 in ABCC11-expressing adenovirus-infected MDCKII cells (S2 Fig). The result shows that the protein levels of non-tagged ABCC11 in the tunicamycin-treated cells were significantly lower than those in non-treated cells.

Since the transfection efficiency in MDCKII cells was low (S1 Fig), we confirmed that our experimental condition was enough to evaluate the effect of N-linked glycosylation on the total protein levels of another ABC transporter ABCG2: WT and Q596, an N-linked glycosylation deficient mutant (S3 Fig). As expected, ABCG2 protein levels of the Q596 mutant were significantly lower than those of the WT, and each ABCG2 protein was mainly localized on the apical membrane of MDCKII cells. These results were consistent with the previous reports showing the contribution of N-linked glycosylation to the protein stability of ABCG2 without any apparent effect on the apical localization of ABCG2 [27, 31].

To further examine the potential role of N-linked glycan in the stability of ABCC11 protein, we constructed three mutants of ABCC11 lacking N-glycosylation site(s). Since ABCC11 protein has two glycosylation sites, N838 and N844 (Fig 1A), either one or both asparagine (N) residues were substituted by glutamine (Q). Immunoblotting analysis demonstrated that, without PNGase F treatment, the molecular weights of all mutants of ABCC11 (Q838, Q844, Q838/844) were lower than that of ABCC11 WT (Fig 3A). In ABCC11 WT, Q838, and Q844, higher molecular weight bands were disappeared and a lower band was appeared with PNGase F treatment (Fig 3A). On the other hand, the band pattern of the Q838/844 mutant was not changed by PNGase F treatment (Fig 3A), indicating that this mutant completely loses the addition of N-linked glycans. At that time, mRNA levels of each ABCC11 were not significantly different (Fig 3B). Immunoblotting analysis addressing PNGase F-treated samples revealed that the protein level of ABCC11 Q838/844 was lower than that of ABCC11 WT (Fig 3C), whereas the protein levels of ABCC11 Q838 and Q844 mutants which each retain one N-glycosylation site showed no difference from that of ABCC11 WT. Densitometric analysis revealed that the ABCC11 protein level of the Q838/844 mutant was about half that of the WT (Fig 3D). This result is consistent with the tunicamycin-dependent decrease of ABCC11 protein level (Fig 2B). Accordingly, at least one N-glycan is necessary for the efficient expression of ABCC11.
N-linked glycosylation is not essential for ABCC11 trafficking to apical membrane.

N-linked glycans attached to the extracellular domain of membrane proteins are often important for protein apical localization [38, 39]. Therefore, we examined the cellular localization of each ABCC11 mutant lacking one or two (all) N-glycans. Confocal microscopic observations revealed that all mutants (Q838, Q844, and Q838/844) localized on the apical membrane of MDCKII cells as ABCC11 WT did (Fig 4). These results suggest that the absence of N-linked glycan did not affect the cellular localization of ABCC11 protein in MDCKII cells. Hence, N-linked glycosylation could not be essential for ABCC11 trafficking to apical membrane but important for the stability of ABCC11 protein, at least, in MDCKII cells.

![Graph showing the effects of tunicamycin on ABCC11 protein levels](image)

**Fig 2.** The effects of tunicamycin, an N-linked glycosylation inhibitor, on lowering the protein levels of ABCC11. Forty-eight hours after the transfection, MDCKII cells transiently expressing ABCC11 wild-type (WT) were cultured with tunicamycin (TNM) (0, 0.8, and 4.0 μg/mL) for further 24 h, then cell lysate samples were prepared after the treatment without (A) or with (B) PNGase F, and then subjected to immunoblotting. α-Tubulin: a loading control. P: PNGase F-treated ABCC11 WT as a control for the band position of non-glycosylated ABCC11 (details are described in Materials and Methods). The signal intensity ratio (ABCC11/α-tubulin) of the immunoreactive bands was determined and normalized to that in TNM-untreated cells (0 μg/mL in B). Data are expressed as mean ± S.D. n = 5. Statistical analyses for significant differences were performed according to Student’s t test (**, P < 0.01 vs control).

doi:10.1371/journal.pone.0157172.g002
N-linked glycosylation of ABCC11 increases protein stability

Since the protein level of the N-glycosylated ABCC11 was higher than that of non-glycosylated ABCC11 (Figs 2 and 3), we next examined whether N-linked glycan affects the protein stability of ABCC11. To inhibit de novo protein synthesis, we treated MDCKII cells transiently transfected with ABCC11 WT or Q838/844 mutant fused with EGFP with cycloheximide, a protein translation inhibitor, for different periods of time (0, 3, 6, and 12 h). Immunoblotting analysis revealed that the protein level of ABCC11 Q838/844 was decreased faster than that of the ABCC11 WT after treatment with cycloheximide (Fig 5). Twelve hours after the cycloheximide treatment, the relative protein level of ABCC11 WT reached about a half of its control (50 ± 7% as compared with t = 0 h, estimated half-life was about 12 h) (Fig 5C). At the same time point, the relative protein level of the Q838/844 mutant was further decreased (26 ± 12% as compared with t = 0 h, estimated half-life was about 6.2 h), indicating that the disruption of N-linked glycan enhances the degradation of the ABCC11 protein. Therefore, N-linked...
glycosylation would increase the stability of ABCC11 protein via the protection from protein degradation systems.

The effect of bafilomycin A1 and MG132 on the protein levels of ABCC11 WT and the Q838/844 mutant

Next, we investigated the molecular basis related to the faster degradation of the Q838/844 mutant than ABCC11 WT. Since most of the membrane proteins are supposed to be degraded in either the lysosomal pathway or proteasomal pathway, we examined the effect of inhibitors for each proteolysis pathway on the ABCC11 protein levels. Forty-eight hours after the transfection, MDCKII cells expressing each ABCC11 protein were incubated for a further 24 h in the presence of 10 nM bafilomycin A1 (BMA) or 2 μM MG132, and then subjected to immuno-blotting analysis (Fig 6). The protein level of ABCC11 WT was significantly enhanced, more than 1.5-fold, when the cells were treated with BMA, whereas there was no significant difference with MG132 treatment (Fig 6A and 6B), suggesting that ABCC11 WT was majorly degraded by the BMA-sensitive lysosomal pathway in MDCKII cells. On the other hand, in the case of the ABCC11 Q838/844 mutant, the protein level was increased about 2-fold when the cells were treated with not only BMA but also MG132 (Fig 6C). To examine the effect of MG132 treatment on the ABCC11 proteins that were mainly localized on the apical membrane of MDCKII cells (Fig 4), 72 h after the transfection of each ABCC11-expressing plasmid when the intracellular accumulation of each overexpressed ABCC11 protein was scarcely detected with confocal microscopic observations (S4 Fig), MDCKII cells were treated with 50 μM CHX in the presence or absence of 2 μM MG132 for further 12 h (Fig 6D). Z-sectioning images of the cells shows that most of ABCC11 WT was detectable as apical membrane protein after the CHX treatment and that the additional MG132 treatment did not cause the apparent change of the localization of ABCC11 WT protein. With the same condition of the confocal microscopic observation, ABCC11 Q838/844 was almost undetectable after the CHX treatment. On the other hand, when treated with both CHX and MG132, the intracellular signals of ABCC11 Q838/844 were detected. These results suggest that the MG132-sensitive proteasomal pathway was enhanced in the Q838/844 mutant, resulting in the lower protein levels (Fig 3) and higher degradation rate (Fig 5) of this N-glycan-deficient mutant as compared with WT.
Low glucose decreases ABCC11 glycosylation and protein level

Recent studies show that N-glycan biosynthesis depends on the utility of sugar substrates such as UDP-GlcNAc, an intracellular metabolite of glucose in the hexosamine pathway [40, 41]. This metabolic pathway is enhanced by an increase of glucose flux into cells [42]. In this context, we hypothesized that the change of extracellular glucose level would affect, as a glycoprotein, the protein levels of matured ABCC11. To verify this hypothesis, 48 h after the transfection, MDCKII cells were further incubated with high (22.5 mM) or low (5 mM) glucose medium for 24 h. Immunoblotting analysis revealed that the amount of glycosylated ABCC11 WT in MDCKII cells cultured in the low glucose condition was significantly lower than that in the high glucose condition.

Fig 5. The effect of N-linked glycosylation on the protein stability of ABCC11. (A and B) The effect of the inhibition of protein translation with cycloheximide (CHX) on the protein levels of ABCC11 wild-type (WT) and the Q838/844 mutant. Seventy-two hours after the transfection, MDCKII cells transiently expressing ABCC11 WT or Q838/844 were further incubated with 50 μM CHX for 0, 3, 6, and 12 h. At the indicated time, cells were collected and stored at -80°C until use. Simultaneously, all cell lysates were prepared and treated without (A) or with (B) PNGase F, and then subjected to immunoblotting. α-Tubulin: a loading control. The signal intensity ratio (ABCC11/α-tubulin) of the immunoreactive bands corresponding to the non-glycosylated form (Non-G) of ABCC11 protein was determined and normalized to the control (t = 0 h) level. Gs, glycosylated forms. (C) Densitometric analysis of protein levels of the ABCC11 WT and the Q838/844 mutant. Values are expressed as % of control (values at 0 h). Data are expressed as mean ± S.D. n = 3 (WT), 4 (Q838/844 mutant). Statistical analyses for significant differences were performed according to Student’s t test (*, P < 0.05 in indicated time points).
the high glucose condition (Fig 7A). The similar tendency in the total protein levels of ABCC11 WT was confirmed by PNGase F treatment (Fig 7B). On the other hand, there was no significant difference in the protein levels of the Q838/844 mutant in MDCKII cells between the different glucose conditions (Fig 7C). In addition, the protein levels of Q838/844 mutant were not higher than those of ABCC11 WT in each glucose condition (S5 Fig). Further immunoblotting analyses revealed that the amount of glycosylated gp135, an endogenous apical membrane protein, in MDCKII cells cultured in the low glucose condition was significantly lower than that in the high glucose condition (S5 Fig). In the case of ABCG2 and GLUT-9b transiently expressed in MDCKII cells, there was no difference in their protein levels between
Fig 7. The effect of extracellular glucose on the protein levels of ABCC11. (A and B) The decrease of the glycosylation and the protein levels of ABCC11 wild-type (WT) expressed in MDCKII cells cultured with a low-glucose medium. (C) The little effect of low-glucose culture on the protein levels of the Q838/844 mutant expressed in MDCKII cells. Forty-eight hours after the transfection, mostly confluent MDCKII cells transiently expressing ABCC11 were cultured with high (H) or low (L) glucose medium for further 24 h. Then, cell lysates were prepared and subsequently subjected to immunoblotting after treatment without (A) or with (B, C) PNGase F. The immunoreactive bands disappeared with PNGase F treatment, corresponding to the glycosylated forms (Gs) of ABCC11 protein. α-Tubulin: a loading control. In densitometric analyses of protein levels of ABCC11 WT and the Q838/844 mutant, the signal intensity ratio (ABCC11/α-tubulin) of the immunoreactive bands was determined and normalized to the control (high glucose) level. P: PNGase F-treated ABCC11 WT as a control for the band position of the non-glycosylated form of ABCC11 (details are described in Materials and Methods). Data are expressed as mean ± S.D. n = 4. Statistical analyses for significant differences were performed according to Student’s t test (**, P < 0.01). N.S.: not significantly different among groups.

doi:10.1371/journal.pone.0157172.g007
the different glucose conditions (S5 Fig). Considering that mRNA expression of each ABCC11 from vectors was exogenously regulated by the CMV promoter in these experiments, the effect of glucose on the ABCC11 protein levels would not be due to transcriptional regulation. Hence, our data suggest that the decrease of extracellular glucose would suppress the glycosylation process of ABCC11, resulting in the decrease in the protein levels of ABCC11 WT.

**Discussion**

In the current study, we investigated the role of N-linked glycosylation in the regulation of ABCC11 protein expressed in polarized MDCKII cells. Biochemical analyses indicated that the disruption of N-linked glycosylation decreased the protein stability of ABCC11 (Figs 2 and 3, S2 Fig). Actually, the N-linked glycan-deficient Q838/844 mutant was degraded faster than WT (Fig 5). On the other hand, the absence of N-linked glycan did not affect the apical localization of ABCC11 in MDCKII cells (Fig 4). Although N-linked glycosylation has been shown to play an important role in the apical localization of a number of proteins, some exceptional cases have also been reported. For example, ABCG2, a physiologically important ABC transporter [43–45], does not require N-linked glycosylation for its apical localization in polarized LLC-PK1 cells [31] and MDCKII cells (S3 Fig), whereas its N-linked glycan contributes to the stabilization of ABCG2 protein [27], which is confirmed again in the present study (S3 Fig). The similar result is also the case with apical sodium-dependent bile acid transporter (ASBT) [25]. These observations support our results demonstrating that N-linked glycan would increase the protein stability of ABCC11, while it would not be essential for apical trafficking of ABCC11. Multiple alignment analysis revealed that the N-linked glycosylation sites corresponding to Asn838 and Asn844 in human ABCC11 are highly conserved in various species (Table 1). The presence and combination of these two glycans might be important for the stability and/or function of ABCC11 expressed in human body.

The results shown in this study lead our deeper understanding of the role of N-linked glycosylation in the ABCC11 regulation. In our previous study using non-polarized Flp-In-293 cells which were generated from HEK293 cells [46], we could determine the N-linked glycosylation

### Table 1. Partial amino acid sequences near the N-linked glycosylation sites in human ABCC11 and the corresponding sequences of its orthologues in mammals.

| Species     | Homology¹ | Sequences                  | Positions | Total amino acids | Access No. |
|-------------|-----------|----------------------------|-----------|-------------------|------------|
| Human       | 100       | WLEQGSGTNSSRESNGTMADL      | 830–850   | 1382              | NP_115972  |
| Chimpanzee  | 98        | WLEQGSGTNSSRESNGTMADL      | 830–850   | 1382              | XP_009429028 |
| Gorilla     | 98        | WLEQGSGTNSSRESNGTMADL      | 830–850   | 1382              | XP_004057661 |
| Monkey      | 91        | WLEQGSGTNSSRESNHTADP       | 830–850   | 1382              | XP_011757555 |
| Goat        | 72        | WLGQSGKNSSQESNWTADP        | 827–847   | 1379              | XP_005692011 |
| Cattle      | 70        | WLGQSGNNSQESNWTTADP        | 827–847   | 1255              | XP_010813025 |
| Horse       | 73        | WLEQGSGANSQESNRTADP        | 833–853   | 1409              | XP_003364699 |
| Dog         | 75        | WLEQGSGTNSSOENNGTADP       | 832–852   | 1384              | XP_003638882 |
| Cat         | 75        | WLGQGSGTNSSOESNGTADP       | 833–853   | 1385              | XP_003998059 |
| Rabbit      | 73        | WLGQGSGTNSSRGSNSSSADP      | 831–851   | 1387              | XP_002721399 |
| Rat         | -         | -                          | -         | -                 | None²     |
| Mouse       | -         | -                          | -         | -                 | None²     |

¹ Homology (%) to the full length of human ABCC11 protein.
² No orthologous gene has been reported to date. Each sequence was obtained from NCBI Protein Database. Reference sequence ID was described in the column of Access No. Putative sites of N-linked glycosylation (Asn-X-Thr/Ser, X ≠ Pro) are indicated by underlining.

doi:10.1371/journal.pone.0157172.t001
sites in ABCC11 protein [16]. At that time, the effect of N-linked glycan on the protein level of ABCC11 was not as clearly observed as compared with the current study, which was probably due to less trafficking of ABCC11 protein to plasma membrane (PM) in non-polarized Flp-In-293 cells than in polarized MDCKII cells. Actually, in the present study, little signal indicating the localization of ABCC11 WT on the PM of non-polarized HEK293 cells was detected (S6 Fig), whereas ABCC11 WT derived from the same plasmid construct was mainly localized on the PM of MDCKII cells (Fig 4). The similar apical localization of ABCC11 was reported in the previous study using the MDCKII cells stably transfected with non-tagged ABCC11 [17], suggesting the presence of EGFP-tag would rarely affect the localization of ABCC11 protein. ABCC11 Q838/844 mutant was also mainly localized on the PM in MDCKII cells. Considering the higher clearance rate of the Q838/844 mutant than that of WT (Figs 5 and 6D), the N-linked glycan-deficient mutant seems to be eliminated from the cell surface rapidly as compared with ABCC11 WT. This interpretation is in line with the similar results observed in several PM proteins including cystic fibrosis transmembrane conductance regulator (CFTR), also known as ABCC7, which belongs to the same (ABCC) subfamily of ABC transporter super-family that includes ABCC11 [25, 27, 47]. Hence, N-linked glycan would enhance the protein level of ABCC11 localized on PM.

We found that N-linked glycosylation increases ABCC11 protein stability and glucose condition may have an impact on the process. In this regard, our data show that the protein levels of N-glycosylated ABCC11 WT were sensitive to the change of glucose condition, whereas those of glycosylation-deficient ABCC11 Q838/844 were not sensitive (Fig 7). In addition, there were two types of glycoproteins, sensitive and non-sensitive to glucose conditions (S5 Fig). Although the current study did not reveal the molecular basis that determines the sensitivity of glycoprotein to glucose conditions, our data suggest that high levels of glucose would enhance ABCC11 glycosylation leading to an increase in ABCC11 protein levels, likely via promoting its protein stability. The similar results were obtained in the following studies both in vitro and in vivo: (i) in vitro exposure to glucose increased the mature glycosylated ASBT protein, but not the core glycosylated ASBT, probably via promoting its stability [25]; (ii) in diabetes model rat, mature glycosylation form of native UT-A1, an urea transporter showing apical localization in polarized cells, was increased with the change in its glycosylation profile [48].

The present study has a limitation that our experimental approach was restricted to the overexpression of ABCC11 due to the non-availability of appropriate cell lines that have the endogenous expression of ABCC11. Considering that the removal of glycosylation site could trigger an ERAD-mediated proteolysis, and that the overexpressed proteins from transfected DNA could evade ERAD sometimes, constitutionally glycosylation-deficient ABCC11 might not be expressed on PM in physiological condition as we observed in the present study. On the other hand, even the endogenous PM protein that is recognized as an ERAD substrate such as ΔF508 CFTR/ABCC7 is reportedly localized on the PM in the ΔF508 homozygous humans [49, 50]. Thus, we have realized that the PM localization of ABCC11 Q838/844 mutant did not mean that this mutant was not an ERAD substrate. In other words, we could not determine whether or not the Q838/844 mutant was degraded by ERAD.

We report here that the N-linked glycan would not be prerequisite for the apical localization of ABCC11, at least, in MDCKII cells. However, the molecular mechanisms regulating the apical targeting of ABCC11 remain to be addressed. Although little information is available, in the case of some other ABCC subfamily proteins such as ABCC2/MRP2, ABCC4/MRP4, and ABCC7/CFTR, an interaction between these ABC transporters and PSD95/Dlg/ZO-1 (PDZ) adapter proteins is supposed to be important for their sorting and/or stabilization on the apical membrane, at least in vitro [51–54]. Actually, those ABCC proteins have a class I PDZ-binding motif (-S/T-X-Φ-COOH; X denotes any amino acid, Φ denotes a hydrophobic acid such as Val, Ile and Leu) at their C-terminus—a consensus sequence in most transporters expressed on
the apical membranes [51]. Although ABCC11 does not have the consensus sequence, its C-terminal sequence (-S-S-L-R-COOH) is highly similar to the PDZ motif. Thus, this PDZ-like sequence might be important for the intracellular regulation of ABCC11 via the interaction with PDZ proteins. Since ABCC11 is a protein of medical importance, any regulatory mechanism controlling the localization of ABCC11 would be the next target of future investigation.

Besides the elucidation of the role of N-linked glycosylation in ABCC11 protein stability, the current study has one clinical implication. Namely, chronic hyperglycemia might exacerbate axillary osmidrosis via the increase of matured ABCC11, since the current study implies that high levels of glucose would enhance the glycosylation of ABCC11, resulting in the increase in ABCC11 protein levels (Fig 7). Indeed, ABCC11 is responsible for the axillary osmidrosis risk probably via the development of human apocrine glands in axilla [55]. Considering the results that the decrease of glucose in culture medium decreased the protein level of ABCC11 (Fig 7A and 7B), maintaining a normal blood glucose level as low as practical might be an effective way to prevent and/or attenuate axillary osmidrosis. Unfortunately, the lack of an Abcc11 gene in rodents gives us a limitation for in vivo investigation in the current study (Table 1), and there is no epidemiological study about the relationship between the axillary osmidrosis phenotype and blood glucose level to our knowledge. Further investigations using ABCC11-transgenic mice and clinical samples would shed light on the implications.

Conclusions

In the current study, we characterized the expression and apical localization of ABCC11 protein with N-linked glycan in polarized MDCKII cells. Our results demonstrate that N-linked glycosylation is important for the protein stability of ABCC11, whereas it is not essential for the apical localization of ABCC11. These results suggest that the inhibition and/or disruption of N-glycan attached to ABCC11 would be a new approach for the treatment of axillary osmidrosis. In addition, physiological alteration of the glucose condition in the human body might affect the axillary osmidrosis phenotype. Further research to verify this potential association between glucose and the ABCC11-related phenotypes would be important.

Supporting Information

S1 Fig. Immunoblotting analysis of non-tagged ABCC11 and ABCC11-EGFP transiently expressed in HEK293 cells and MDCKII cells. HEK293 cells and MDCKII cells were transiently transfected with non-tagged ABCC11 wild-type (WT) or ABCC11 WT-EGFP. Cell lysates were prepared 72 h after the transfection, and subsequently subjected to immunoblotting using the anti-ABCC11 antibody or the anti-EGFP antibody after treatment with or without PNGase F. Each exposure time for signal detection is indicated in parentheses. Mock: non-inserted pcDNA3.1/hygro(-) plasmid, EGFP: non-inserted pEGFP-N1 plasmid, α-Tubulin: a loading control. Anti-ABCC11 antibody could detect both non-tagged ABCC11 and ABCC11-EGFP expressed in HEK293 cells. On the other hand, these proteins expressed in MDCKII were undetectable with the anti-ABCC11 antibody, whereas ABCC11-EGFP expressed in MDCKII was detected with anti-EGFP antibody. Relationship between the band intensity and exposure time in each immunoblotting image suggest that the anti-EGFP antibody was more sensitive than the anti-ABCC11 antibody, and that the total protein levels of transfected product in MDCKII cells were significantly lower than those in HEK293 cells. (TIF)

S2 Fig. The effect of tunicamycin, an N-linked glycosylation inhibitor, on lowering the protein levels of non-tagged ABCC11. (A) Effect of adenovirus infection on the viability of
MDCKII cells. MDCKII cells were seeded at a density of \(1.4 \times 10^5\) cells/cm\(^2\) onto 12-well cell culture plate. Twelve hours after the seeding, the cells were infected with adenovirus at indicated MOIs. After 48 h of a further incubation, WST-8 assay was performed to evaluate the cellular viability in each well. Data are expressed as mean ± S.D. \(n=6\). Statistical analyses for significant differences were performed according to Bartlett’s test, followed by Dunnett’s test. N.S.: not significantly different as compared with non-infected (0 MOI) control. (B) Immunoblotting analysis of non-tagged ABCC11 expressed in adenovirus-infected MDCKII cells. Forty-eight hours after the adenovirus infection at non-toxic 200 MOI, the MDCKII cells transiently expressing non-tagged ABCC11 WT were cultured with fresh medium with or without tunicamycin (TNM) (4.0 μg/mL) for further 24 h. Subsequently, cell lysate samples were prepared and treated with or without PNGase F, and then subjected to immunoblotting using the anti-ABCC11 antibody. The protein levels of non-tagged ABCC11 in the tunicamycin-treated cells were significantly lower (15% ± 14% as compared with non-treated control, \(n=3\) ) than those in non-treated cells. α-Tubulin: a loading control. Results are representative of three independent sample sets.

S3 Fig. The effect of the disruption of N-linked glycosylation sites on the protein levels and localization of ABCG2. (A) Immunoblotting and densitometric analysis of protein levels of ABCG2 WT and glycosylation-deficient Q596 mutants expressed in MDCKII cells 72 h after the transfection. Cell lysate samples were prepared and treated with or without PNGase F, and then subjected to immunoblotting. The immunoreactive bands, corresponding to the glycosylated forms (Gs, glycosylation at N596) of the ABCG2 protein, disappeared with PNGase F treatment. The signal intensity ratio (ABCG2/α-tubulin, a loading control) of the immunoreactive bands corresponding to non-glycosylated (Non-G) ABCG2 was determined and normalized to the WT level. Data are expressed as mean ± S.D. \(n=3\). Statistical analyses for significant differences were performed according to Student’s t test (**, \(P<0.05\)). (B) Apical localization of ABCG2 and Q596 mutant expressed in MDCKII cells 72 h after the transfection. An endogenous apical membrane marker gp135 was immunostained using the anti-gp135 antibody (red). Nuclei were stained with TO-PRO-3 iodide (gray). All panels show the Z-sectioning images. As expected, each ABCG2 protein was localized on the apical membrane of MDCKII cells, which is consistent with previous reports as described in the main text.

S4 Fig. Confocal microscopic observation of ABCC11 WT and Q838/844 mutant expressed in MDCKII cells 72 h after the plasmid transfection. Overexpressed ABCC11 WT and Q838/844 mutant were localized on the apical membrane of MDCKII cells. On the other hand, there is little signal indicating the intracellular accumulation of each protein. Nuclei were stained with TO-PRO-3 iodide (gray). The upper and middle panels are en face images focused at the top and middle of the cells, respectively. The bottom panels show the Z-sectioning images (XZ). Bars: 5 μm.

S5 Fig. The effect of extracellular glucose on the protein levels of apical membrane proteins. (A) ABCC11 wild-type (WT) and N838/844 mutant, (B) endogenous gp135, (C) ABCG2 WT, and (D) GLUT-9b WT. Forty-eight hours after the transfection, mostly confluent MDCKII cells were cultured with high (H) or low (L) glucose medium for further 24 h. Then, cell lysates were prepared and subsequently subjected to immunoblotting after treatment with or without PNGase F. The immunoreactive bands disappeared with PNGase F treatment, corresponding to the glycosylated form(s) (Gs) of each protein. α-Tubulin: a loading control. (B-D) In
densitometric analyses of protein levels of each apical membrane protein, the signal intensity ratio (target protein/α-tubulin) of the immunoreactive bands corresponding to the non-glycosylated (non-G) form was determined and normalized to the control (high glucose) level. Data are expressed as mean ± S.D. n = 4 (B), 3 (C and D). Statistical analyses for significant differences were performed according to Student’s t test (*, P < 0.05). N.S.: not significantly different among groups.

(TIF)

S6 Fig. Localization of ABCC11 in non-polarized HEK293 cells. HEK293 cells were transiently transfected with ABCC11 wild-type (WT)-EGFP, and imaged by confocal microscopy 72 h after the transfection. In order to visualize the plasma membranes (PMs), cells were pre-treated with CellMask™ Orange Plasma Membrane Stain (Life technologies) (1:2000 diluted in PBS (-)) for 10 min at room temperature. Bars: 5 μm.

(TIF)

Acknowledgments
The authors thank Dr. Chie Umatani (University of Tokyo) for her critical reading of this manuscript. Y.T. was a research fellow of Japanese Society for the Promotion of Science (JSPS).

Author Contributions
Conceived and designed the experiments: YT TT. Performed the experiments: YT. Analyzed the data: YT. Contributed reagents/materials/analysis tools: YT HM. Wrote the paper: YT TT TI HS.

References
1. George A, editor. ABC Transporters—40 Years on. 1 ed. Switzerland: Springer International Publishing; 2016.
2. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015; 14(1):29–44. doi: 10.1038/nrd4461 PMID: 25475361
3. Ueda K. ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem. 2011; 75(3):401–9. PMID: 21389634
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215–36. doi: 10.1038/nrd3028 PMID: 20190787
5. Borst P, Ellerink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537–92. PMID: 12045106
6. Toyoda Y, Ishikawa T. MRP8 (ABCC11). In: Ishikawa T, Kim R, Konig J, editors. Pharmacogenomics of Human Drug Transporters: Clinical Impacts: John Wiley & Sons, Inc.; 2013. p. 387–400.
7. Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiota. 2008, 38 (7–8):833–62. doi: 10.1080/00498250701883514 PMID: 18668432
8. Ishikawa T, Toyoda Y, Yoshiura K, Niikawa N. Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion. Front Genet. 2013; 3:306. doi: 10.3389/fgene.2012.00306 PMID: 23316210
9. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007; 453(5):675–84. PMID: 16868766
10. Toyoda Y, Ishikawa T. Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem. 2010; 10(8):617–24. PMID: 21182469
11. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005; 67(2):545–57. PMID: 15537867
12. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxyadenosine and 9-(2'-deoxy-2'-fluoro-arabino-hexosyl)adenine. J Biol Chem. 2003; 278(32):29509–14. PMID: 12764137

13. Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015; 125:217–43. doi: 10.1016/bs.acr.2014.10.007 PMID: 25640272

14. Yabuuchi H, Shimizu H, Takayanagi S, Ishikawa T. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun. 2001; 288(4):933–9. PMID: 11689999

15. Tammur J, Prades C, Arnold I, Rzhetsky A, Hutchinson A, Adachi M, et al. Two new genes from the human ATP-binding cassette superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene. 2001; 273(1):89–96. PMID: 11483364

16. Toyoda Y, Sakurai A, Mitani Y, Nakashima M, Yoshiura K, Nakagawa H, et al. Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine ear wax type? FASEB J. 2009; 23(6):2001–13. doi: 10.1096/fj.09-129098 PMID: 19383836

17. Bortfeld M, Rius M, Konig J, Herold-Mende C, Nies AT, Keppler D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006; 137(4):1247–57. PMID: 1659813

18. Yoshiura K, Kinoshita A, Ishida T, Ninokata A, Ishikawa T, Kaname T, et al. A SNP in the ABCC11 gene is the determinant of human ear wax type. Nat Genet. 2006; 38(3):324–30. PMID: 16444273

19. Miura K, Yoshiura K, Miura S, Shimada T, Yamasaki K, Yoshida A, et al. A strong association between human ear wax-type and apocrine colostrum secretion from the mammary gland. Hum Genet. 2007; 121(5):631–3. PMID: 17394018

20. Martin A, Saathoff M, Kuhn F, Max H, Terstegen L, Natsch A. A functional ABCC11 allele is essential in the biochemical formation of human axillary odor. J Invest Dermatol. 2010; 130(2):529–40. doi: 10.1038/jid.2009.254 PMID: 19710689

21. Inoue Y, Mori T, Toyota Y, Sakurai A, Ishikawa T, Mitani Y, et al. Correlation of axillary osmidrosis to a SNP in the ABCC11 gene determined by the Smart Amplification Process (SmartAmp) method. J Plast Reconstr Aesthet Surg. 2010; 63(8):1369–74. doi: 10.1016/j.bjps.2009.06.029 PMID: 19625321

22. Nakano M, Miwa N, Hirano A, Yoshiura K, Niikawa N. A strong association of axillary osmidrosis with the wet ear wax type determined by genotyping of the ABCC11 gene. BMC Genet. 2009; 10:42. doi: 10.1186/1471-2156-10-42 PMID: 19650936

23. Weerapana E, Imperiali B. Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology. 2006; 16(6):91R. PMID: 16510493

24. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126(5):855–67. PMID: 16950566

25. Muthusamy S, Malhotra P, Hosameddin M, Dudeja AK, Borthakur S, Saksena S, et al. N-glycosylation is essential for ileal ASBT function and protection against proteases. Am J Physiol Cell Physiol. 2015; 308(12):C964–71. doi: 10.1152/ajpcell.00023.2015 PMID: 25855079

26. Suzuki S, Shuto T, Sato T, Kaneko M, Takada T, Suico MA, et al. Inhibition of post-translational N-glycosylation by HRD1 that controls the fate of ABCG5/8 transporter. Sci Rep. 2014; 4:4258. doi: 10.1038/srep04258 PMID: 24584735

27. Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyota Y, Koshiba S, Ishikawa T. Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J. 2009; 276(24):7237–52. doi: 10.1111/j.1742-4658.2009.07423.x PMID: 19909340

28. Li LB, Chen N, Ramamoorthy S, Chi L, Cui XN, Wang LC, et al. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem. 2004; 279(20):21012–20. PMID: 15020413

29. Nakagawa H, Toyota Y, Wakabayashi-Nakao K, Tamaki H, Osumi M, Ishikawa T. Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. J Pharm Sci. 2011; 100(9):3602–19. doi: 10.1002/jps.22615 PMID: 21567408

30. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012; 8(10):610–21. doi: 10.1038/nrrheum.2012.144 PMID: 22945592

31. Takada T, Suzuki H, Sugiyama Y. Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm Res. 2005; 22(3):458–64. PMID: 15835752

32. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-
transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002; 277(8):6497–503. PMID: 11748225

33. Stiburkova B, Miyata H, Zavada J, Tomcik M, Pavelka K, Storkanova G, et al. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. Rheumatology (Oxford). 2016; 55(1):191–4.

34. Ito N, Ito K, Ikebuchi Y, Toyoda Y, Takada T, Hisaka A, et al. Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport. Pharm Res. 2015.

35. Meder D, Shevchenko A, Simons K, Fullekrug J. Gp135/podocalyxin and NHERF-2 participate in the formation of a preapical domain during polarization of MDCK cells. J Cell Biol. 2005; 168(2):303–13. PMID: 15642748

36. Ojakian GK, Schwimmer R. The polarized distribution of an apical cell surface glycoprotein is maintained by interactions with the cytoskeleton of Madin-Darby canine kidney cells. J Cell Biol. 1988; 107(6 Pt 1):2377–87.

37. Toyoda Y, Tamai M, Kashikura K, Kobayashi S, Fujiyama Y, Soga T, et al. Acetaminophen-induced hepatotoxicity in a liver tissue model consisting of primary hepatocytes assembling around an endothelial cell network. Drug Metab Dispos. 2012; 40(1):169–77. doi: 10.1124/dmd.111.041137 PMID: 22010217

38. Vagin O, Kraut JA, Sachs G. Role of N-glycosylation in trafficking of apical membrane proteins in epithelia. Am J Physiol Renal Physiol. 2009; 296(3):F459–69. doi: 10.1152/ajprenal.90340.2008 PMID: 18971212

39. Scheiffele P, Peranen J, Simons K. N-glycans as apical sorting signals in epithelial cells. Nature. 1995; 378(6552):96–8. PMID: 7477300

40. Denzel MS, Storm NJ, Gutschmidt A, Baddi R, Hinze Y, Jarosch E, et al. Hexosamine pathway metabolites enhance protein quality control and prolong life. Cell. 2014; 156(6):1167–78. doi: 10.1016/j.cell.2014.01.061 PMID: 24630720

41. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007; 129(1):123–34. PMID: 17418791

42. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54 (6):1615–25. PMID: 15919781

43. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012; 3:764. doi: 10.1038/ncomms1756 PMID: 22473008

44. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009; 1(5):ra11. doi: 10.1126/scitranslmed.3000237 PMID: 20368174

45. Toyoda Y, Takada T, Suzuki H. Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep. 2016; 6:24586. doi: 10.1038/srep24586 PMID: 27087417

46. Wakabayashi-Nakao K, Tamura A, Koshiba S, Toyoda Y, Nakagawa H, Ishikawa T. Production of cells with targeted integration of gene variants of human ABC transporter for stable and regulated expression using the Flp recombinase system. Methods Mol Biol. 2010; 648:139–59. doi: 10.1007/978-1-60761-756-3_9 PMID: 20700710

47. Glozman R, Okiyoneda T, Mulvihill CM, Rini JM, Barriere H, Lukacs GL. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol. 2009; 184 (6):847–62. doi: 10.1083/jcb.200808124 PMID: 19307599

48. Chen G, Howe AG, Xu G, Frohlich O, Klein JD, Sands JM. Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization. FASEB J. 2011; 25(12):4531–9. doi: 10.1096/fj.11-185991 PMID: 21965602

49. Bronsveld I, Mekus F, Bijman J, Ballmann M, Greipel J, Hundrieser J, et al. Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology. 2000; 119(1):32–40. PMID: 10889152

50. Dray-Charier N, Paul A, Scoaazec JY, Veissiere D, Mergety M, Capeau J, et al. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Hepatology. 1999; 29(6):1624–34. PMID: 10347100

51. Sugiura T, Shimizu T, Kijima A, Minakata S, Kato Y. PDZ adaptors: their regulation of epithelial transporters and involvement in human diseases. J Pharm Sci. 2011; 100(9):3620–35. doi: 10.1002/jps.22575 PMID: 21538352
52. Emi Y, Nomura S, Yokota H, Sakaguchi M. ATP-binding cassette transporter isoform C2 localizes to the apical plasma membrane via interactions with scaffolding protein. J Biochem. 2011; 149(2):177–89. doi: 10.1093/jb/mvq131 PMID: 21059598

53. Favia M, Guerra L, Fanelli T, Cardone RA, Monterisi S, Di Sole F, et al. Na+/H+ exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in human airway CFBE41o- cells. Mol Biol Cell. 2010; 21(1):73–86. doi: 10.1091/mbc.E09-03-0185 PMID: 19889841

54. Hoque MT, Cole SP. Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. Cancer Res. 2008; 68(12):4802–9. doi: 10.1158/0008-5472.CAN-07-6778 PMID: 18559527

55. Toyoda Y, Gomi T, Nakagawa H, Nagakura M, Ishikawa T. Diagnosis of Human Axillary Osmidrosis by Genotyping of the Human ABCC11 Gene: Clinical Practice and Basic Scientific Evidence. BioMed Res Int. 2016; 2016:7670483. doi: 10.1155/2016/7670483 PMID: 27057547